Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
Ian N BruceRonald F Van VollenhovenKonstantina PsachouliaCatharina LindholmEmmanuelle MahoRaj TummalaPublished in: Lupus science & medicine (2023)
Anifrolumab treatment was associated with sustained improvements in overall SLE disease activity and skin responses versus placebo from Week 8, which likely led to greater glucocorticoid reductions in the anifrolumab versus placebo groups from Week 20. These findings provide insights to physicians and patients on when to expect potential clinical responses following anifrolumab treatment.
Keyphrases
- disease activity
- phase iii
- systemic lupus erythematosus
- rheumatoid arthritis
- placebo controlled
- open label
- clinical trial
- primary care
- rheumatoid arthritis patients
- end stage renal disease
- double blind
- ankylosing spondylitis
- newly diagnosed
- ejection fraction
- juvenile idiopathic arthritis
- randomized controlled trial
- peritoneal dialysis
- prognostic factors
- phase ii
- big data
- climate change
- study protocol
- patient reported outcomes